Hims & Hers Health, Inc.
HealthcareNYSE:HIMS · New York Stock Exchange
-$1.91 today
Vol 16.37M · Avg 28.06M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $128.4M +1.8% | $126.0M +635.3% | -$23.5M +64.1% | -$65.7M +39.0% | -$107.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $54.5M +218.9% | $17.1M +79.6% | $9.5M +27.3% | $7.5M +83.4% | $4.1M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$13.0M +79.0% | -$61.6M -474123.1% | -$13.0K +97.8% | -$594.0K +82.5% | -$3.4M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $135.2M +46.5% | $92.3M +39.7% | $66.1M +54.3% | $42.8M -36.3% | $67.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$29.2M -137.1% | $78.6M +277.6% | $20.8M +246.7% | -$14.2M -510.9% | $3.5M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | -$13.7M +67.0% | -$41.6M -4513.3% | -$902.0K +88.7% | -$8.0M +16.9% | -$9.6M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $30.3M -30.7% | $43.7M +496.8% | $7.3M -42.4% | $12.7M +29.1% | $9.9M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$45.7M -159.8% | $76.5M +431.5% | $14.4M +176.1% | -$18.9M -685.6% | $3.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $24.0M +1895.0% | -$1.3M -313.7% | $626.0K -82.8% | $3.6M +92.4% | $1.9M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $300.0M +19.5% | $251.1M +241.7% | $73.5M +377.0% | -$26.5M +22.9% | -$34.4M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$226.0M -328.5% | -$52.8M -99.1% | -$26.5M -265.6% | -$7.2M -44.7% | -$5.0M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$145.2M -843.1% | -$15.4M | $0 +100.0% | -$459.0K +99.0% | -$46.5M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$745.8M -364.5% | -$160.6M -2.1% | -$157.2M +16.2% | -$187.7M +29.6% | -$266.6M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $108.7M -48.2% | $209.7M +22.2% | $171.6M -25.4% | $230.1M +42.2% | $161.8M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$16.5M -49.1% | -$11.1M -19.7% | -$9.3M -104.5% | -$4.5M -8.6% | -$4.2M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$1.0B -5280.9% | -$19.0M -57.3% | -$12.1M -134.9% | $34.7M +122.2% | -$156.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $918.8M | $0 | $0 | $0 -100.0% | $1.2M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $17.5M | $0 | $0 | $0 -100.0% | $272.7M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$90.0M -8.3% | -$83.0M -4054.0% | -$2.0M | $0 +100.0% | -$22.0M | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$116.7M -370.3% | -$24.8M -161.8% | -$9.5M +71.4% | -$33.1M -97.1% | -$16.8M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $729.6M +776.5% | -$107.8M -839.8% | -$11.5M +65.4% | -$33.1M -114.1% | $235.0M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $3.4M +1345.9% | -$270.0K -2354.5% | -$11.0K +79.2% | -$53.0K +27.4% | -$73.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $8.0M -93.5% | $123.9M +148.4% | $49.9M +299.5% | -$25.0M -156.5% | $44.3M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $74.0M -62.7% | $198.3M +322.1% | $47.0M +239.1% | -$33.8M +14.3% | -$39.4M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Moderna, Inc.
NASDAQ:MRNA
$19.93B
Penumbra, Inc.
NYSE:PEN
$12.52B
Align Technology, Inc.
NASDAQ:ALGN
$12.51B
Revvity, Inc.
NYSE:RVTY
$11.11B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.85B
Baxter International Inc.
NYSE:BAX
$10.73B
The Ensign Group, Inc.
NASDAQ:ENSG
$8.67B
Bio-Techne Corporation
NASDAQ:TECH
$8.46B
Qiagen N.V.
NYSE:QGEN
$7.65B
HealthEquity, Inc.
NASDAQ:HQY
$7.37B
SEC Filings
Recent regulatory filings
No filings found.
Does HIMS generate free cash flow?
Hims & Hers Health, Inc. (HIMS) generated $73.96M of free cash flow in fiscal 2025.
How much operating cash flow does HIMS produce?
Operating cash flow was $300.01M, before capital expenditures of $226.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.